At the Clinical Threshold: MDMA Has a VA Trial, Ibogaine Has 71% Abstinence Data, and Psilocybin Has Two States. Insurance Has None of This.

On June 2, 2026, the U.S. Department of Veterans Affairs announced enrollment in a randomized controlled trial testing MDMA-assisted therapy for PTSD and alcohol use disorder in American veterans. The study is actively recruiting from multiple VA medical centers. It includes an active placebo arm. It is, by any reasonable measure, the most significant official federal acknowledgment that the therapy the FDA rejected less than two years ago might be worth pursuing at scale.

Lykos Therapeutics had approximately 75 employees remaining when the VA launched its trial. The company cut three-quarters of its workforce after the FDA’s August 2024 Complete Response Letter. The drug is still being developed. The science survived the corporate collapse.

The government came last, but it came

The timing carries its own irony. MDMA was used in therapeutic settings in the 1970s and early 1980s, classified as Schedule I in 1985, and then studied quietly by advocacy-driven researchers for three decades while veterans with PTSD flew to clinics in Mexico, Jamaica, and Canada for treatments the country that sent them to war refused to study or fund. The federal government’s first major trial of MDMA-assisted therapy for a dual indication — PTSD and alcohol use disorder simultaneously — launched in June 2026, two years after the FDA said no.

The VA trial is driven partly by an executive order directing federal agencies to accelerate research into treatments for serious mental illness, including post-combat trauma. It is designed to enroll approximately 80 veterans, comparing MDMA-assisted therapy against identical psychotherapy with an active placebo. Primary completion is targeted for late 2028.

What makes the trial notable beyond its funding source is the dual indication. Veterans with PTSD are approximately twice as likely to develop alcohol use disorder as the general population. The two conditions create a treatment-resistant knot that the separate evidence bases for PTSD and AUD treatment don’t handle well in isolation: treating the PTSD without addressing the AUD misses a primary driver of relapse and distress, and treating the AUD without addressing the underlying trauma leaves the person exposed to chronic stress that predictably triggers return to use. MDMA-assisted therapy’s documented effect on fear extinction and social trust — the pharmacological and psychological mechanisms researchers believe underlie its efficacy — are potentially relevant to both conditions. The VA trial is designed to find out whether that potential is real.

The results will not arrive for years. But they will arrive from an institution that Congress, the FDA, and the private insurance industry have historically treated with a different kind of credibility than they give to advocacy-backed pharmaceutical companies. If the VA data shows what the earlier clinical trials suggest, the downstream pressure on FDA review and insurance coverage will be substantial.

The FDA’s rejection didn’t say the therapy doesn’t work

It’s worth being specific about what the FDA found when it issued its Complete Response Letter to Lykos in August 2024 — because the distinction between “the therapy doesn’t work” and “the evidence package doesn’t meet our standards” matters for understanding where the field is now.

The FDA did not find that MDMA-assisted therapy is ineffective. The Phase 3 trial published in Nature Medicine in 2021 found that 71 percent of MDMA-assisted therapy participants no longer met PTSD diagnostic criteria at the end of treatment, compared to 48 percent in the placebo-plus-therapy arm. That is a real and substantial effect, large enough to matter clinically even accounting for the limitations of psychedelic trial design.

What the FDA found instead was a set of structural problems with the evidence package. First, a functional unblinding issue: MDMA’s effects are perceptible, participants frequently know whether they received the drug, and this creates a placebo response problem that the existing trial designs don’t fully address. This is not a problem unique to Lykos — it applies to every psychedelic therapy trial currently being designed, and solving it will require either better placebo compounds or fundamentally different statistical approaches. Second, a data integrity concern at one clinical site that was investigated separately and found to involve conduct issues. Third, a request for at least one additional Phase 3 trial with enhanced blinding verification before re-submission.

Second, a data integrity concern at one clinical site that was investigated separately and found to involve conduct issues.

Lykos’s 75-percent workforce reduction and its commitment to a redesigned Phase 3 trial are a company trying to survive long enough to generate the additional evidence the FDA asked for. Whether it succeeds depends on whether investors maintain confidence through several more years of clinical development with no guaranteed approval at the end.

The FDA’s concerns were legitimate. They were not the same as saying MDMA doesn’t work for PTSD. That distinction is being swallowed in coverage that treats the rejection as a verdict on the therapy rather than a judgment about one company’s evidence package.

The ibogaine data is the one that deserves more attention

In January 2026, Stanford researchers published results from a Phase II clinical trial of ibogaine treatment for opioid use disorder. The abstinence rate at six months was 71 percent. The sample was 120 patients with treatment-resistant OUD — people who had already tried and failed conventional treatments including buprenorphine, methadone, and naltrexone. Seventy-one percent abstinence at six months, in treatment-resistant OUD, is a number that does not appear anywhere else in the addiction medicine literature.

Ibogaine is not a comfortable substance. It is also a Schedule I drug in the United States, illegal for any purpose including clinical use without a DEA-approved research protocol. It causes serious cardiac arrhythmias — QTc prolongation — in a small percentage of patients, which is the primary reason it has resisted clinical development: you cannot administer it safely without intensive cardiac monitoring, and cardiac monitoring adds cost and risk that most clinical trial frameworks struggle to manage. The unmodified plant-derived compound has been administered for decades in Mexico, Jamaica, and Portugal through clinics operating outside U.S. regulation, at costs ranging from $3,000 to $10,000 per treatment, largely to Americans who had exhausted other options.

DemeRx, backed by ATAI Life Sciences, has received FDA clearance for a Phase II/III investigational new drug study of its ibogaine derivative, engineered to preserve the therapeutic mechanism while reducing cardiac risk. Their Phase III completion is targeted for 2028; a potential NDA submission could follow by 2029 or 2030.

What ibogaine does neurologically is still being mapped, which is itself a remarkable statement about a compound that has been in use for two decades. It acts at sigma-1 receptors, kappa-opioid receptors, and multiple serotonin receptor subtypes simultaneously — a mechanistic fingerprint unlike any existing opioid treatment. Researchers believe the combination creates what they describe informally as a neurochemical reset: a period of dramatic reduction in craving and withdrawal symptoms that, in some patients, appears to persist well beyond the drug’s metabolic clearance. The Stanford data suggests the reset holds. Whether it holds at scale, and whether the DemeRx formulation preserves the effect while reducing the cardiac risk, is what the trials will answer.

Oregon and Colorado are expensive experiments for the people who can afford experiments

Oregon’s Measure 109 psilocybin services program has licensed more than 300 facilitators and 100 service centers statewide. Colorado’s Prop 122 healing centers opened in September 2024; by early 2026, approximately 50 licensed facilities operate primarily in Denver, Boulder, and ski resort corridors. Between the two states, people seeking psilocybin-assisted therapy have more options than existed two years ago.

The sessions cost $800 to $3,000 depending on provider. Insurance does not cover them. There are no subsidies for lower-income clients. Oregon’s first-year demographic data showed clients were disproportionately white, college-educated, and financially stable.

The irony is precise. Psilocybin’s strongest addiction evidence — Bogenschutz et al.’s 2022 JAMA Psychiatry trial showing an 83 percent reduction in heavy drinking days versus 51 percent for placebo in a randomized trial — involves a population with alcohol use disorder. Psilocybin’s proposed mechanism for addiction treatment (default mode network disruption, reduction in rigid thought patterns, increased psychological flexibility under the right therapeutic conditions) is not a mechanism that selectively benefits people who can afford $2,000. But the delivery system is structured as a cash market for the financially secure.

But the delivery system is structured as a cash market for the financially secure.

New Jersey signed a psilocybin therapy pilot program in January 2026, with $6 million in hospital-based funding. South Dakota passed psilocybin therapy legislation in March 2026. Twenty-six additional states have legislation pending. The state-by-state expansion is accelerating. The insurance question is not.

LSD received FDA Breakthrough Therapy designation for generalized anxiety disorder in May 2026 — MindMed’s MM120 formulation, with Phase 2b results showing a 65 percent clinical response rate and 48 percent remission in GAD patients. Compass Pathways, whose COMP360 (synthetic psilocybin) has positive Phase 3 data in treatment-resistant depression, is now targeting an FDA approval decision for late 2026 or early 2027, earlier than previously anticipated. The clinical threshold is real and approaching.

The access question is the only question that matters now

In 2026, the psychedelic therapy field has produced, in aggregate, some of the most striking data in addiction medicine’s recent history. MDMA works for PTSD — well enough that the VA is running a trial for a dual indication. Psilocybin reduces heavy drinking by 83 percent in a randomized controlled trial. Ibogaine achieves 71 percent abstinence in treatment-resistant OUD. LSD has breakthrough designation for anxiety. Compass may be months from the first FDA approval of a psychedelic as a prescription drug.

What none of this has produced is an insurance billing code, a Medicaid coverage pathway, a treatment navigation standard, or a plan for how a person in recovery in Phoenix, Arizona — ranked 49th for behavioral health access — finds and affords any of it.

The clinical threshold is being crossed. The access infrastructure that would allow crossing it to mean something for the 48.5 million Americans with a substance use disorder hasn’t been built. That is the work of the next five years: for insurers who need to decide whether psilocybin-assisted therapy for AUD is a reimbursable medical intervention; for regulators who need to update scheduling and clinical practice guidelines; for treatment navigation platforms that need to begin modeling for this category of provider; and for the field itself, which has generated the data and now has to generate the delivery.

The VA trial launched on June 2, 2026. The first veteran walked into a federal medical center to receive MDMA with the explicit support of the government that had classified the drug as Schedule I forty years ago. What happens next — how quickly FDA acts, how states cover it, how much it costs and who can access it — will determine whether the breakthrough data translates into the breakthrough treatment the field keeps describing.

---

Coverage of the psychedelics-empathogens treatment landscape is ongoing at /newsroom/substances/psychedelics-empathogens.